Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies

作者
Ismail Kasujee,Giovanni Bader
出处
期刊:The European respiratory journal [European Respiratory Society]
卷期号:44: 3479- 被引量:1
摘要

Introduction Omalizumab, an anti-IgE monoclonal antibody is recommended for long-term treatment of patients with moderate-to-severe allergic asthma that are identified by the physician9s global evaluation of treatment effectiveness (GETE) tool after 16 weeks of therapy. This post-hoc pooled analysis investigated the effect of omalizumab vs. placebo (PBO) on exacerbations in GETE responders (patients with good/excellent rating). Methods Data from 5 randomised, double-blind, placebo-controlled phase 3 studies were pooled and annualised clinically significant exacerbation (any worsening of asthma considered by the treating physician to require systemic corticosteroids) rates were analysed in GETE responders and non-responders to omalizumab and PBO therapy. The number needed-to-treat (NNT) to save one exacerbation in 1 year was calculated. Results Omalizumab significantly reduced the annualised clinically significant exacerbation rate in responders (n=553) by 63% vs. the overall PBO group (n=801) and by 51% vs. the PBO responders (n=306; Figure). The NNT to save one clinically significant exacerbation in 1 year for omalizumab was 1.19 vs. the overall PBO group and 1.96 vs. PBO responders. Conclusions Omalizumab responders, as identified by GETE, are associated with significantly lower exacerbations rates compared with those on placebo. GETE is a tool that can help identify those who benefit from omalizumab therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DW发布了新的文献求助10
刚刚
1秒前
艾格的应助被身处人海采纳,获得10
1秒前
1秒前
2秒前
2秒前
bml发布了新的文献求助10
2秒前
2秒前
3秒前
DW发布了新的文献求助10
3秒前
静默发布了新的文献求助10
3秒前
DW发布了新的文献求助10
3秒前
4秒前
完美世界的应助被Jerry采纳,获得10
4秒前
Lucas的应助被谨慎的南露采纳,获得10
5秒前
11发布了新的文献求助10
5秒前
瘦瘦靴发布了新的文献求助10
6秒前
大大大大宝凌完成签到,获得积分10
6秒前
6秒前
斯文败类的应助被喔喔佳佳L采纳,获得20
6秒前
DW发布了新的文献求助10
6秒前
6秒前
DW发布了新的文献求助10
6秒前
大方飞瑶完成签到 ,获得积分10
7秒前
DW发布了新的文献求助10
7秒前
DW发布了新的文献求助10
7秒前
yf完成签到,获得积分10
7秒前
思源的应助被wang采纳,获得10
7秒前
believe发布了新的文献求助10
8秒前
8秒前
8秒前
9秒前
9秒前
9秒前
DW发布了新的文献求助10
10秒前
DW发布了新的文献求助10
10秒前
DW发布了新的文献求助10
10秒前
慕青的应助被FaFa采纳,获得10
10秒前
DW发布了新的文献求助10
10秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188221
求助须知:如何正确求助?哪些是违规求助? 9576025
关于积分的说明 21845049
捐赠科研通 7786165
什么是DOI,文献DOI怎么找? 3435226
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482157